epratuzumab   

GtoPdb Ligand ID: 8088

Synonyms: 90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name)
Compound class: Antibody
Comment: Epratuzumab is a humanized monoclonal antibody. It is derived from the murine IG2a monotclonal antibody, LL2 (EPB-2). Epratuzumab has antineoplastic and antiinflammatory actions [1].
The antibody can be conjugated with tetraxetan (DOTA) which allows chelation of radionucleotides such as yttrium-90 [5].
Immunopharmacology Comments
Epratuzumab was investigated for antiinflammatory actions in SLE, but was found not to be effective following Phase 3 trial evaluation [3,6].
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Epratuzumab is being investigated for antiinflammatory actions in SLE.